Available from stock

Docetaxel

SKU: D0371

Category: Antibiotics

Synonyms: Taxotere® , NSC 628503 , RP 56976 , N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol; 114977-28-5
CAS-Number: C₄₃H₅₃NO₁₄
Molecular Formula: 807.88
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥97% (HPLC)
Appearance: White to off-white powder
Identity: 1H-NMR

Properties

Solvents: DMSO, ethanol

Documentation

Safety Data Sheet (SDS): CDX D0371 MSDS.pdf

Shipping: AMBIENT
Short Term Storage: +4°C
Long Term Storage: -20°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at -20°C.

Transportation: Not dangerous goods

Description: Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the β-tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.
Smiles: CC(C)(OC(N[C@H]([C@H](C(O[C@H]1C[C@@]([C@H]([C@@H]([C@@]2(C([C@@H](C3=C1C)O)=O)C)[C@]4([C@@H](C[C@@H]2O)OC4)OC(C)=O)OC(C5=CC=CC=C5)=O)(C3(C)C)O)=O)O)C6=CC=CC=C6)=O)C
InChi Key: ZDZOTLJHXYCWBA-VCVYQWHSSA-N
References: (1) M.C. Bissery, et al., Cancer Res. 51, 4845 (1991) , (2) R. Bruno & G.J. Sanderink, Cancer Surv. 17, 305 (1993) (Review) , (3) K. Gelmon, Lancet 344, 1267 (1994) (Review) , (4) M.E. Trudeau, Can. J. Oncol. 6, 443 (1996) (Review) , (5) I.A. Avramis, et al., Anticancer Res. 21, 2281 (2001) , (6) M. Aapro & E. Rowinsky, Anticancer Drugs 12, S1 (2001) (Review) , (7) P.B. Cassidy, et al., Clin. Cancer Res. 8, 846 (2002) , (8) M.S. Si, et al., Invest. New Drugs 21, 281 (2003) , (9) B. Ramaswamy & S. Puhalla, Drugs Today 42, 265 (2006) (Review) , (10) H. Hernandez-Vargas, et al., Cell Cycle 6, 780 (2007) (Review) , (11) H. Ching-Hsia, et al., Toxicol. Sci. 145, 59 (2015)
InChi: InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1

Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the β-tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.

SKU: D0371 Category: Antibiotics

Additional information

Additional information

Synonyms	Taxotere®, NSC 628503, RP 56976, N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
Purity	≥97% (HPLC)
Appearance	White to off-white powder
CAS-Number	114977-28-5
Molecular Formula	C43H53NO14
Molecular Weight	807.88
Identity	1H-NMR
Solvents	DMSO, ethanol
Smiles	CC(C)(OC(N[C@H]([C@H](C(O[C@H]1C[C@@]([C@H]([C@@H]([C@@]2(C([C@@H](C3=C1C)O)=O)C)[C@]4([C@@H](C[C@@H]2O)OC4)OC(C)=O)OC(C5=CC=CC=C5)=O)(C3(C)C)O)=O)O)C6=CC=CC=C6)=O)C
InChi Key	ZDZOTLJHXYCWBA-VCVYQWHSSA-N
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at -20°C.
Transportation	Not dangerous goods
References	(1) M.C. Bissery, et al., Cancer Res. 51, 4845 (1991), (2) R. Bruno & G.J. Sanderink, Cancer Surv. 17, 305 (1993) (Review), (3) K. Gelmon, Lancet 344, 1267 (1994) (Review), (4) M.E. Trudeau, Can. J. Oncol. 6, 443 (1996) (Review), (5) I.A. Avramis, et al., Anticancer Res. 21, 2281 (2001), (6) M. Aapro & E. Rowinsky, Anticancer Drugs 12, S1 (2001) (Review), (7) P.B. Cassidy, et al., Clin. Cancer Res. 8, 846 (2002), (8) M.S. Si, et al., Invest. New Drugs 21, 281 (2003), (9) B. Ramaswamy & S. Puhalla, Drugs Today 42, 265 (2006) (Review), (10) H. Hernandez-Vargas, et al., Cell Cycle 6, 780 (2007) (Review), (11) H. Ching-Hsia, et al., Toxicol. Sci. 145, 59 (2015)
InChi	InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
Quantity	5 mg, 25 mg, Bulk